Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (June 10th Preview)
-
Sanofi oncology and late-stage pipeline setback
Sanofi has stopped a Phase 3 trial of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) after an independent monitoring board concluded the therapy was unlikely to achieve sufficient efficacy. The MOBILIZE study was testing the anti-inflammatory medicine in patients who were not helped by standard of care. The decision came without new safety concerns. The halt adds to a string of late-stage disappointments for Sanofi and sets up new strategic questions for riliprubart, which was acquired from Bioverativ in 2018. Sanofi said it is evaluating whether to continue another Phase 3 study, VITALIZE, designed to compare riliprubart and IVIg. Analysts framed the update as particularly notable for complement-inhibitor competitors in CIDP, including Dianthus Therapeutics, which is developing a similar approach targeting C1. Investors appeared to weigh the possibility that study design—not only biology—may be the deciding factor for efficacy outcomes in this class.
-
IPO surge for Parabilis and record-setting public-market appetite
Parabilis Medicines—formerly FogPharma—has priced an upsized $670 million biotech IPO, setting a new record for venture-backed drug companies going public. The offering totals 33.3 million shares at $20 each, after the company increased its initial plan, positioning Parabilis for a Nasdaq debut under the ticker PBLS. The proceeds are earmarked to advance the Wnt/β-catenin pathway inhibitor zolucatetide (FOG-001) through multiple clinical settings, including planned Phase 3 work in desmoid tumors. The company also intends to expand early clinical programs spanning rare genetic and oncology indications with additional pathway degraders. The IPO comes as investors appear more selective than broad-based, with capital concentrating on later-stage clinical momentum and institutional backing. Parabilis has previously raised more than $800 million across multiple rounds, including a $305 million Series F earlier this year.
-
Big Pharma expands into molecular glue with Orionis deal
Novartis has signed a second molecular-glue partnership with Orionis Biosciences, adding $40 million upfront and up to $1.4 billion in milestone-based consideration. The deal focuses on Orionis’s ability to address challenging therapeutic targets across multiple disease areas. The collaboration builds on an earlier agreement between Novartis and Orionis, signaling continued internal confidence in the molecular-glue platform approach. For Orionis, the structure provides near-term funding while tying additional payments to clinical and development milestones. For the broader biotech market, the second deal reinforces Big Pharma’s willingness to re-up on platform bets when early target-validation work looks promising enough to sustain a pipeline commitment.
-
Ultrasound-based gene delivery gains clinical funding momentum
SonoThera has raised $125 million to advance its ultrasound-based, non-viral gene therapy platform into the clinic. The funding round is led by Vida Ventures, with participation from large pharma venture arms including UCB, Bayer, Otsuka, and Johnson & Johnson. The company plans to move two lead programs toward clinical evaluation: Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease. SonoThera’s approach relies on microbubbles to enhance delivery, aiming to avoid limitations seen in viral vectors such as liver toxicity risk and immune recognition that can limit dosing. The financing underscores how established gene-therapy investors are continuing to back alternative delivery technologies that could expand use cases beyond rare disease populations.
-
GSK acquires Nuvalent to build a lung cancer franchise
GSK has agreed to buy Nuvalent for roughly $10.6 billion in cash, a move designed to add two late-stage lung cancer programs to its pipeline. The deal brings ROS1 inhibitor zidesamtinib and ALK blocker neladalkib, both under FDA review with potential 2026 decision timelines. GSK also gains early-stage exposure to NVL-330, a potential HER2-targeting inhibitor in Phase 1, and a preclinical portfolio. The acquisition includes an expected launch pathway for the lead assets if they win approval, with an explicit emphasis on building profit contribution as new products scale. The Nuvalent buyout also signals how Big Pharma is leaning into highly selective targeted oncology strategies to challenge entrenched competitors’ franchises, especially in biomarker-defined non-small cell lung cancer.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.